Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
INVOKAMET is a fixed-dose combination tablet containing canagliflozin (SGLT2 inhibitor) and metformin hydrochloride (biguanide) approved in 2014. It treats type 2 diabetes mellitus by dual mechanism: inhibiting renal glucose reabsorption and reducing hepatic glucose production. The combination provides complementary glycemic control in patients inadequately managed by monotherapy.
Product is in peak revenue phase with modest Part D spending ($22M, 19K claims in 2023), indicating stable mature market position with moderate team investment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers
Worked on INVOKAMET at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOE in ~4 years — strategic planning for patent cliff underway
INVOKAMET offers stable, mature-stage careers in commercial execution and healthcare economics but limited growth trajectory; roles focus on defending market share against competitors and managing LOE transition. Professionals joining should expect emphasis on pricing resilience, payer relationships, and managed decline strategy rather than launch excitement or indication expansion.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo